CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Creative Medical Technology Holdings, Inc. announced a public offering of up to 3,045,685 shares of common stock and 6,091,371 Public Warrants, along with up to 3,045,685 pre-funded warrants. The offering, priced at an assumed $1.97 per share and accompanying Public Warrants, is expected to generate approximately $5.34 million in net proceeds. The company plans to use these funds to advance its clinical trials for chronic lower back pain and Type I Diabetes, further develop its iPScelz™ program, and for general corporate purposes. The offering is being conducted on a "best efforts" basis through Roth Capital Partners, LLC.

Creative Medical Technology Holdings, Inc. is launching a best efforts public offering of up to 3,045,685 shares of common stock, along with public warrants to purchase up to 6,091,371 shares and pre-funded warrants for up to 3,045,685 shares, at an assumed price of $1.97 per unit. The offering aims to raise approximately $5.34 million in net proceeds to fund ongoing clinical trials for chronic lower back pain and Type 1 Diabetes, develop its iPSCelz™ program, and for general corporate purposes. The company has recently achieved several clinical and regulatory milestones, including FDA Fast Track designation for CELZ-201-DDT and Orphan Drug Designation for ImmCelz™ (CELZ-100). However, the filing highlights significant risks, potential dilution, and the best efforts nature of the offering.

Creative Medical Technology Holdings announced that the FDA has cleared an expansion of its ADAPT clinical trial for CELZ-201 (Olastrocel), targeting chronic lower back pain. The expansion adds 15 patients with ongoing but moderate opioid use, leveraging a new AI-enabled monitoring system. This follows positive interim 180-day data from the original cohort and positions the company for Phase 3 discussions with the FDA. The company expects to complete enrollment of the new cohort by the end of summer 2026 using existing resources.

Creative Medical Technology Holdings announced the next operational milestone for Project PHOENIX, its regulatory-approved, AI-driven CELZ-Biodefense Regenerative BioDefense Initiative. The program is now moving into nationwide virtual participant onboarding and data collection, designed to support an initial cohort of at least 1,000 U.S. veterans exposed to toxic hazards. The platform leverages a decentralized mobile-app model and field-capable logistics, integrating multi-omics profiling and AI to identify biomarkers and therapeutic targets for drug discovery, all while utilizing existing infrastructure for capital efficiency.

Creative Medical Technology Holdings, Inc. reported a net loss of $(1.40) million for the three months ended March 31, 2026, an improvement from $(1.64) million in the prior year. However, revenues for the quarter dropped to $0 from $3,000 in Q1 2025. The company's cash balance decreased to $5.72 million from $7.21 million at December 31, 2025, and total assets also declined.

Creative Medical Technology Holdings, Inc. (CELZ) announced breakthrough positive results from its pilot study of Ultrasome™, a cell-free regenerative therapy for knee osteoarthritis. The study achieved its primary endpoint, with an industry-leading 93% of patients showing clinically meaningful improvements in mobility and pain reduction, and no serious adverse events. Ultrasome™ is derived from the company's GMP-manufactured CELZ-201, expanding its platform into scalable, off-the-shelf therapies for the large, underserved osteoarthritis market. CELZ plans to expand clinical execution and evaluate strategic pathways toward commercialization and partnerships.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company confirmed its status as a non-accelerated filer and a smaller reporting company, indicating its size and reporting obligations. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was $4,633,334, with 3,696,668 shares outstanding as of March 20, 2026.